anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses a method processing fleece-flower root by simultaneously combining prepared rehmannia root and prepared rehmannia root juice and relates to the field of traditional Chinese medicinal materials. The method processing fleece-flower root by simultaneously combining prepared rehmannia root and prepared rehmannia root juice utilizes juice from prepared rehmannia root steaming to steam &#39;prepared rehmannia root liquid manufactured fleece-flower root&#39;, achieves steaming effect of two kinds of medicines, saves rehmannia root medicinal resource waste during prepared rehmannia root juice manufacture, and saves time, labor and energy. The method comprises the steps of directly letting steam in, mixing yellow rice or millet wine with the fleece-flower root, placing the fleece-flower root on a lower layer of a steaming container, and steaming the fleece-flower root through prepared rehmannia root juice flowed from an upper layer rehmannia root mixed with the yellow rice or millet wine. Finally, steamed fleece-flower root can not only achieve processing with wine, but also achieves processing with prepared rehmannia root juice; the appearance is black, and the effect of even and consistent inside and outside. Simultaneously, rehmannia root achieves the effect of steaming with wine, the black is like lacquer, the sweetness is like candy, the operation is practicable, and time, labor and energy are saved. Steamed fleece-flower root and rehmannia root are good in color and high in yield and can both achieve requirements of traditional processing.
FIELD: chemistry.SUBSTANCE: group of inventions relates to adhesive hydrogel compositions intended for oral application. The hydrophilic pressure-sensitive bioadhesive is a non-covalent complex of a film-forming polymer with at least one of the following complementary components: cross-linking polymer agent, cross-linking oligomer agent, low-molecular weight substance, or with a mixture of at least two of said components, where the film-forming polymer and the cross-linking polymer agent are selected from a class of hydrophilic polymers. Components of the bioadhesive are taken in an amount which enables to obtain a complex which is characterised by adhesion to the surface of teeth and the lack of adhesion towards other tissues in the oral cavity with particular values glass transition temperature, modulus of elasticity G?, loss tangent, swelling degree in aqueous medium and swell ratio. The film-forming hydrophilic polymer is preferably contained in a higher concentration than other components of the adhesive, wherein the latter have complementary reactive functional groups which are capable of forming non-covalent hydrogen, electrostatic or ionic bonds with functional groups of the hydrophilic film-forming polymer. In a swollen state, the &#34;smart&#34; hydrophilic pressure-sensitive adhesive is softer than the dental substrate but harder than the mucosal tissues in the oral cavity. Also disclosed is a dental care composition which contains the pressure-sensitive bioadhesive and one or more active agents, such as teeth whitening agents, fluoride sources, antibacterial agents etc. The preferred teeth whitening agent is a peroxide.EFFECT: composition can be used as teeth whitening film-strips or gels.56 cl, 3 tbl, 27 ex
1319998 Spiro-benzocyclone acetic acids ROUSSEL UCLAF 4 Sept 1970 [5 Sept 1969] 42544/70 Heading C2C Novel compounds of the Formula I wherein R is hydrogen or a C 1-4  straight or branched alkyl, R 3  is hydrogen, chlorine, C 1-4  alkoxy or trifluoro methyl, Y is methylene, oxygen or sulphur and n is 2, 3 or 4, esters and salts thereof may be prepared by (1) reducing the keto group of compound II to a methylene group, (2) hydrogenating a compound III wherein X is oxygen or methylene and optionally thereafter converting the compound I wherein R is hydrogen to an ester thereof, and treating the ester with an alkylating agent to form I wherein R is C 1-4  alkyl. The intermediate III may be prepared by dehydration of the compound IV which in turn is produced by reduction of the compound II wherein Y is oxygen or methylene. The intermediate II may be prepared by (1) cyclizing a compound V (2) hydrolysing a compound XI or (3) hydrolysing a compound XVIII The intermediate V may be prepared by hydrolysis of a compound VI wherein R 4  and R 5  are the same or different and are C 1-6  alkyl or together with the adjacent nitrogen form a heterocyclic ring. The compound VI may be prepared by reacting a compound VII with sulphur and R 4 R 5 NH the compound VII wherein n is 3 or 4 being produced by chain extension of the compound wherein n is 2 or 3, the compound VII wherein n is 2 being produced by decarboxylation of the hydrolysis product of compound VIII wherein R&lt;SP&gt;11&lt;/SP&gt; is a ketal group and R&lt;SP&gt;111&lt;/SP&gt; is an alkyl group, the compound VIII being prepared by an alkyl cyanoacetate IX with a ketal X Alternatively the intermediate V, wherein Y is oxygen or methylene, may be produced by hydrolysis of compound XII the compound XII wherein n is 3 or 4 being produced by chain extension of XII wherein n is 2 or 3, the compound XII wherein n is 2 being prepared by reacting compound XIII wherein Hal is chlorine or bromine, with an alkali metal cyanide, the compound XIII being produced by brominating or chlorinating compound XIV which is produced by decarboxylating the hydrolysis product of compound XV which in turn is produced via an appropriately substituted Grignard reagent similar to compound VIII. The intermediate XI may be prepared by cyclizing compound XII under hydrolysing conditions. The intermediate XVIII may be prepared by reacting a compound XIX wherein Hal is chlorine or bromine with alkali metal cyanide, the compound XIX being produced by halogenation and cyclization in either order preceded by chain extension if necessary of XIV, similarly to the previously described processes. Pharmaceutical compositions of the compounds I show anti-inflammatory and analgesic activity and may be mixed with the usual excipients or further ingredients having analogous activity and administered orally, parenterally, rectally, permucosally or topically.
PURPOSE: To obtain a medicinal agent with release of the active substance uniformly delayed overall in high reproducibility by bringing a medicinal agent comprising a compression-molded matrix composed of the powdery active substance and an auxiliary into contact with lower alcohol vapor. CONSTITUTION: A compression-molded mixture as solid matrix composed of a powdery active substance and a powdery acrylic ester polymer or vinyl ester polymer as auxiliary insoluble to the body fluid [at least gastric juice (pref. plus intestinal juice)] existing at a site to be applied to, is exposed to a vapor phase consisting of a lower alcohol, pref. a 2-4C alcohol, esp, ethanol to obtain the objective medicinal agent with release of the active substance uniformly delayed. The acrylic ester polymer is pref. a homopolymer or copolymer made from &gt;=3wt.% of a (meth)acrylic 1-8C(pref. 1-4C)alkyl ester and &lt;=70wt.% of an α,β-ethylenically unsaturated comonomer copolymerizable therewith.
NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10&lt;4&gt; dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at &gt;=pH4 and precipitate at &lt;=pH3.5, Adsorptivity: adsorbed on strong ion exchanger. USE:A remedy of severe infectious diseases, virus infectious diseases, malignant tumor, etc. PREPARATION:For example, Staphylococcus aureus Cowan III type is cultured and the bacterium is crushed using an ultrasonic disintegrator followed by centrifugation for separation of the supernatant. The separated supernatant is ultrafiltrated for concentration and the resultant concentrated solution is dialyzed and subsequently subjected to the affinity chromatography method using a human IgG-bonded agarose column to collect the non-adsorbed fraction. To the obtained non-adsorbed fraction ammonium sulfate is added and the resultant precipitate is collected and redissolved. The obtained solution is fractionated using a strong ion exchange column for purification, thus obtaining the objective bioactive substance MP-A.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a microcapsule suitable for therapeutic or diagnostic use.  &lt;P&gt;SOLUTION: The microcapsule has a wall thickness of no more than 500 nm and bulk density of no more than 0.2 g/cm&lt;SP&gt;3&lt;/SP&gt;, is aerodynamically light, is suitable for delivery to the lung or for diagnosis by ultrasonic waves, and is especially suitable for formulation with an inspirator. When the microcapsule includes a therapeutic agent, the microcapsule is quickly discharged and then uptaken in lung, absolutely contrastively to any controlled release formulation, thus avoiding drug inclusion. Furthermore, if the microcapsule includes only a wall-forming substance and does not include the therapeutic agent, the microcapsule is especially suitable for ultrasonic wave imaging. The relatively thin wall of the microcapsule exhibits echogenicity improved in appearance.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a trichogen containing the extract of Aristolochia debilis Sieb.et. Zucc, high in safety and excellent in the trichogenous effect. SOLUTION: This trichogen contains the whole grass extract of Aristolochia debilis Sieb.et Zucc, a glabrous perennial liane herb belonging to the genus Aristolochia in the family Aristolochiaceae in an amount of 0.001-10wt.%. The extract is obtained by drying or grinding the plant bodies, extracting the dried or ground plant bodies with a water-soluble organic solvent such as ethanol or acetone or with a water-containing water-soluble organic solvent containing the alcohol, the acetone or THF preferable in a concentration of &gt;=50wt.% for 7-10 days at room temperature or for 4-8hr at a higher temperature, and subsequently subjecting the extract to a suction filtration treatment and a vacuum concentration treatment. The addition of a skin peripheral vasodilator (e.g. carpronium chloride) to the agent expresses a more preferable trichogenous effect.  The trichogen is excellent in safety, because a skin trouble, etc., caused by the long period employment of the trichogen is not recognized.
1356911 Purification and functionation of carcinoembryonic antigen F HOFFMANN-LA ROCHE &amp; CO AG 1 June 1971 [1 June 1970 27 Jan 1971 12 April 1971] 18309/71 Heading A5B A purified human carcinoembryonic antigen is prepared by a process comprising: a) homogenizing adenocarcinoma tissue; b) removing solid from the homogenisate; c) treating the supernatant with a glycoprotein solvent (e.g. perchloric acid); d) discarding the precipitate and clarifying the solution; c) subjecting the clarified solution to osmosis against an aqueous solution of a polyethylene glycol which has a M.W. of approx. 15,000 to 20,000 and a softening point of about 60C; f) dissolving the resulting rentate in an aqueous buffer of pH 5-9; g) chromatographing the solution from f) sequentially on two different gel columns, the one being an agarose gel comprising approximately 6% agarose and having a particle size of 40-210 microns and the other being a water-insoluble, cross-linked, hydrophilic, dextran polymer gel; h) collecting the fractions having a spectrophotometric adsorption peak of 280mÁ and a M.W. of about 200,000 to about 500,000. These fractions may be combined and subjected to further treatment to produce two different active compounds, namely &#34;Human carcinoembryonic antigen A and B&#34;. Suitable treatment comprises osmosis against a polyethylene glycol solution as described above, dissolution in a buffer, e.g. ammonium acetate at pH4, clarification and chromatography on a mixed bed ion-exchange column comprising microgranular diethylaminoethyl cellulose and carboxymethyl cellulose, using e.g. ammonium acetate/sodium chloride (pH 4) as eluant.
PURPOSE:To obtain a composition for oral cavity application exhibiting excellent effect to prevent the formation of bacterial plaque and dental caries by compounding cetyl pyridinium chloride and an N&lt;alpha&gt;-long-chain acyl basic amino acid lower alkyl ester. CONSTITUTION:The objective composition can be produced by compounding &gt;=0.0002wt.% and usually &lt;=1wt.% of cetyl pyridinium chloride and &gt;=1/5 pts.wt., usually 1/5 to 10 pts.wt. (based on 1 pt. wt. of the cetyl pyridinium chloride) of an N&lt;alpha&gt;-long-chain acyl basic amino acid lower alkyl ester, mixing with desired components by conventional method and forming in the form of a drug. It can be used as tooth powder, tooth paste, gargle or troche or sprayed into oral cavity as aerosol. It can also be used as a tooth-application agent by impregnating in a dental floss or a toothpick. The adsorption of the antibacterial cetyl pyridinium chloride to the surface of tooth can be promoted by this process.
A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and/or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX/15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours. Also disclosed are n-3 DPA-derived resolvins for use in the treatment or prevention of cardiovascular disease, and methods for measuring the levels of n-3 DPA-derived resolvins and/or the expression or activity of adenosine or 5-LOX/15-LOX in biological samples obtained from a subject for assessing the subject&#39;s risk of cardiovascular disease.
Competence in the nursing profession is of great importance in quality care practices, nurse leadership in teamwork, academic and clinical performance, both in terms of professionalism and the quality of life of patients. Competence in the profession is possible through clinical practices that allow gaining bedside experience after evidence-based theoretical knowledge. While clinical practices are of great importance for students to gain professional knowledge and skills, they also appear as a cause of stress. Care of the sick individual, not being able to find an adequate guide, lack of a role model, negative relationships with healthcare professionals in the clinic, clinical conditions being inadequate for students\&amp;amp;#39; knowledge and skills for practice, fear of making mistakes and failure in students, ethical dilemmas they witness in clinical practices and negative emotions as a result of ethical dilemmas. Many situations such as this increase stress in students. Adding moral distress to students\&amp;amp;#39; existing stress sources reduces clinical motivation. In this context, determining nursing students; attitudes towards clinical practices has an important place in improving students; motivation and perceptions of their professional lives. It is impossible to eliminate MD in the nursing profession, which focuses on people and touches people;s quality of life. In this case, it is of great importance to understand MD both in professional life and in nursing education, to agree on precautions and to ensure that students are strengthened in terms of MD. It will also affect the attitudes of students who are successful in MD management towards clinical practices at the desired level, and this will strengthen the quality of life of the individual and the society. This study aimed to investigate the effect of MD on attitudes towards clinical practices in nursing students who have started to provide clinical experience. It is anticipated that the results of this research will contribute to the literature and faculty members who take an active role in nursing education.
A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers&#39; yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.
An apparatus and method for subsequent optimization of radiosurgery and radiotherapy is provided. The invention includes administering a metalloporphyrin to the patient, and then creating a 3-dimensional mapping of tissue through use of PET or SPECT. Malignant and pre-malignant tissue has an affinity for the metalloporphyrin. During treatment, real-time images are also provided which are compared to the previous 3-dimensional mapping. Creation of the real-time images is also achieved through PET or SPECT wherein a metalloporphyrin is administered to the patient. Total administration of radiation is calculated by summing radiation from the inetalloporphyrins and from the radiosurgery/radiotherapy. The amount of radiation delivered by the metalloporphyrins and by the radiosurgery/radiotherapy are adjustable based on a patient&#39;s response to the dual delivery.
A novel approach to the development of a personalized vaccine. This approach is based on: A) sequencing of the gag gene from an HIV-infected individual treated with antiretroviral therapy; B) sequencing of the HLA alleles of the same individual; C) selecting the epitopes recognized by the individual&#39;s own HLA Class I within the highly-conserved Gag 256-377 , Gag 147-169  and/or Gag 225-251  amino acid sequences. An original algorithm that designs the target peptide for the vaccine starting from viral and HLA sequences of an individual with HIV/AIDS, forms the core of the present invention. The original algorithm makes extensive use of existing open- source software for protein design. The peptides designed in this manner and accordingly synthesized may be exploited as a therapeutic vaccine against HIV/AIDS. Vehicles for such peptides may be an individual&#39;s own dendritic cells pulsed with the peptide combination or a specific viral or DNA vector leading to intracellular expression of the viral peptides. The present vaccine approach may contribute to control of viremia once antiretroviral therapies are suspended.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide hop tea containing pharmacologically effective ingredients (prenylflavonoid) to a person who does not want to take alcohol but wants to take pharmacologically effective ingredients contained in the hop, and effective for preventing menopausal disorders and geriatric diseases.  &lt;P&gt;SOLUTION: The pharmacological effectiveness of prenylflavonoid in the hop is noted. The hop of the Saaz species is boiled for 10 min (1 litter water:1 gram hop). The obtained aqueous suspension is allowed to stand for 20 min at room temperature, filtered to remove unnecessary solids and added with sugar to adjust bitterness to be easily taken, and is provided as a liquid tea. The hop to be employed is a solid condensed type used in beer brewing, thus extraction of the effective ingredients is easily performed and excels in costs.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
An article for the sustained release of an insecticide into the ambient air comprises an elastomeric matrix, with the insecticide dissolved in the matrix. The matrix material has a modulus between about 104 Pa and about 108 Pa at 23 DEG  C., and a glass transition temperature less than 0 DEG  C. The matrix comprises polyurethane formed by reacting hydroxyl-terminated polybutadiene or polyisoprene and 4,4&#39; diphenylmethane diisocyanate, and the insecticide is 2,2&#39; dichlorovinyl dimethyl phosphate. The insecticide-containing matrix is contained in a plastic bottle, and typically protected against inadvertent skin contact by means of a dermal barrier. The article also comprises means for activating the article such that, prior to activation, release of insecticide into the ambient air is prevented, whereas such release can take place after activation. Exemplary activation means comprise a metal foil seal of the plastic bottle. The article is effective in controlling insect infestation (e.g., ants, fire ants, bees, wasps, cockroaches) in enclosures, e.g., enclosures of the type used to protect outdoor utility equipment.
The present invention relates to a composition comprising a seed extract of Chionanthus retusus Lindl. &amp; Paxton as an active ingredient for preventing or treating an aging-related degenerative disease. The seed extract of Chionanthus retusus Lindl. &amp; Paxton in accordance with the present invention has undergone antioxidation effect measurement experiments (experiment example 1) such as an electron donating ability (EDA) measurement experiment, a superoxide dismutase (SOD)-like activity measurement experiment, a nitrite scavenging ability measurement experiment, a xanthine oxidase inhibition ability measurement experiment, etc., and influence measurement experiments (experiment example 2) such as a collagenase inhibition ability measurement experiment and an elastase inhibition ability measurement experiment to verify an excellent suppression effect for an aging-related degenerative disease, specifically, skin aging such as wrinkles. Therefore, the seed extract of Chionanthus retusus Lindl. &amp; Paxton is useful for a pharmaceutical composition for preventing or treating an aging-involved degenerative disease, health functional food, or health supplement food.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H or halogen; the ring A is pyridine ring or tetrahydropyridine ring) and its acid addition salt. EXAMPLE:1,2,3,4,8,9,10,12-Octahydroimidazo[2,1-b]pyrido[2,3-f]quinazol in-9-one. USE:An antithrombotic agent. It has blood platelet coagulation suppressing activity, and useful for the remedy and prevention of vascular thrombosis, prevention of temporary local anemia, and the prevention of blood platelet thrombosis during the use of a prosthesis (e.g. artificial heart, artificial kidney, etc.). PROCESS:The compound of formula I (A is pyridine ring) can be prepared by heating the compound of formula II (A&#39; is pyridine ring; R&lt;3&gt; is lower alkyl; X is halogen) together with NH3 in a lower alcohol solvent such as methanol, ethanol, etc. in a sealed tube at 100-150 deg.C. Some of the compounds of formula I have especially high solubility in water, and can be administered parenterally, especially by intravenous injection in the form of aqueous solution.